APO Research
Talk to an analyst

APO RESEARCH · REPORT

Polycystic Ovary Syndrome (PCOS) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Polycystic Ovary Syndrome (PCOS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025199 pages

Choose your research edition.

Industry ResearchPolycystic Ovary Syndrome (PCOS) Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Polycystic Ovary Syndrome (PCOS) Drugs Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Polycystic Ovary Syndrome (PCOS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Polycystic Ovary Syndrome (PCOS) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Polycystic Ovary Syndrome (PCOS) Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Polycystic Ovary Syndrome (PCOS) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Polycystic Ovary Syndrome (PCOS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Polycystic Ovary Syndrome (PCOS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Polycystic Ovary Syndrome (PCOS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Polycystic Ovary Syndrome (PCOS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs include Teva Pharmaceutical Industries Limited, Sanofi, Novartis AG, Merck KGaA, Ferring Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc., Bristol Myers Squibb Co., BIOCAD and AstraZeneca plc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Polycystic Ovary Syndrome (PCOS) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Polycystic Ovary Syndrome (PCOS) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Polycystic Ovary Syndrome (PCOS) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Polycystic Ovary Syndrome (PCOS) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Polycystic Ovary Syndrome (PCOS) Drugs Segment by Company

Teva Pharmaceutical Industries Limited

Sanofi

Novartis AG

Merck KGaA

Ferring Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc.

Bristol Myers Squibb Co.

BIOCAD

AstraZeneca plc.

Addex Therapeutics Ltd.

Polycystic Ovary Syndrome (PCOS) Drugs Segment by Type

Anti-Obesity

Antiandrogens

Antidepressant

Oral Contraceptives

Insulin-Sensitizing Agent

Polycystic Ovary Syndrome (PCOS) Drugs Segment by Application

Hospital

Clinic

Polycystic Ovary Syndrome (PCOS) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Polycystic Ovary Syndrome (PCOS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Polycystic Ovary Syndrome (PCOS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Polycystic Ovary Syndrome (PCOS) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Polycystic Ovary Syndrome (PCOS) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Polycystic Ovary Syndrome (PCOS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Polycystic Ovary Syndrome (PCOS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Polycystic Ovary Syndrome (PCOS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Polycystic Ovary Syndrome (PCOS) Drugs Industry Trends Table 2. Polycystic Ovary Syndrome (PCOS) Drugs Industry Drivers Table 3. Polycystic Ovary Syndrome (PCOS) Drugs Industry Opportunities and Challenges Table 4. Polycystic Ovary Syndrome (PCOS) Drugs Industry Restraints Table 5. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Manufacturers Table 9. Global Polycystic Ovary Syndrome (PCOS) Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Polycystic Ovary Syndrome (PCOS) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Polycystic Ovary Syndrome (PCOS) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Polycystic Ovary Syndrome (PCOS) Drugs Manufacturers, Product Type & Application Table 13. Global Polycystic Ovary Syndrome (PCOS) Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Polycystic Ovary Syndrome (PCOS) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Anti-Obesity Table 17. Major Manufacturers of Antiandrogens Table 18. Major Manufacturers of Antidepressant Table 19. Major Manufacturers of Oral Contraceptives Table 20. Major Manufacturers of Insulin-Sensitizing Agent Table 21. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2021-2026) & (W Units) Table 23. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2027-2032) & (W Units) Table 24. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Type (2021-2026) Table 25. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Type (2027-2032) Table 26. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 27. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type (2021-2026) & (W Units) Table 28. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type (2027-2032) & (W Units) Table 29. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 34. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2021-2026) & (W Units) Table 35. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2027-2032) & (W Units) Table 36. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Application (2021-2026) Table 37. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Application (2027-2032) Table 38. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 39. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application (2021-2026) & (W Units) Table 40. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application (2027-2032) & (W Units) Table 41. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 44. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region (2021-2026) & (W Units) Table 45. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Region (2021-2026) Table 46. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Forecasted by Region (2027-2032) & (W Units) Table 47. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Polycystic Ovary Syndrome (PCOS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 49. North America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2026) & (W Units) Table 50. North America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2027-2032) & (W Units) Table 51. Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2026) & (W Units) Table 53. Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2027-2032) & (W Units) Table 54. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2026) & (W Units) Table 56. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2027-2032) & (W Units) Table 57. South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2026) & (W Units) Table 59. South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2027-2032) & (W Units) Table 60. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Region (2027-2032) Table 65. Teva Pharmaceutical Industries Limited Company Information Table 66. Teva Pharmaceutical Industries Limited Business Overview Table 67. Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio Table 69. Teva Pharmaceutical Industries Limited Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio Table 74. Sanofi Recent Development Table 75. Novartis AG Company Information Table 76. Novartis AG Business Overview Table 77. Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio Table 79. Novartis AG Recent Development Table 80. Merck KGaA Company Information Table 81. Merck KGaA Business Overview Table 82. Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio Table 84. Merck KGaA Recent Development Table 85. Ferring Pharmaceuticals, Inc. Company Information Table 86. Ferring Pharmaceuticals, Inc. Business Overview Table 87. Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio Table 89. Ferring Pharmaceuticals, Inc. Recent Development Table 90. Crinetics Pharmaceuticals, Inc. Company Information Table 91. Crinetics Pharmaceuticals, Inc. Business Overview Table 92. Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio Table 94. Crinetics Pharmaceuticals, Inc. Recent Development Table 95. Bristol Myers Squibb Co. Company Information Table 96. Bristol Myers Squibb Co. Business Overview Table 97. Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio Table 99. Bristol Myers Squibb Co. Recent Development Table 100. BIOCAD Company Information Table 101. BIOCAD Business Overview Table 102. BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio Table 104. BIOCAD Recent Development Table 105. AstraZeneca plc. Company Information Table 106. AstraZeneca plc. Business Overview Table 107. AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio Table 109. AstraZeneca plc. Recent Development Table 110. Addex Therapeutics Ltd. Company Information Table 111. Addex Therapeutics Ltd. Business Overview Table 112. Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio Table 114. Addex Therapeutics Ltd. Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Polycystic Ovary Syndrome (PCOS) Drugs Distributors List Table 118. Polycystic Ovary Syndrome (PCOS) Drugs Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Polycystic Ovary Syndrome (PCOS) Drugs Product Image Figure 2. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales (2021-2032) & (W Units) Figure 5. Global Polycystic Ovary Syndrome (PCOS) Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Polycystic Ovary Syndrome (PCOS) Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Anti-Obesity Image Figure 9. Antiandrogens Image Figure 10. Antidepressant Image Figure 11. Oral Contraceptives Image Figure 12. Insulin-Sensitizing Agent Image Figure 13. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 28. North America Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Canada Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Mexico Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 35. France Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 36. U.K. Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Italy Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Netherlands Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Country (2021-2032) Figure 41. China Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Japan Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 43. South Korea Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Southeast Asia Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 45. India Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Australia Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Saudi Arabia Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Turkey Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Argentina Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 54. UAE Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Egypt Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Chile Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Polycystic Ovary Syndrome (PCOS) Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Polycystic Ovary Syndrome (PCOS) Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-Obesity
  • Antiandrogens
  • Antidepressant
  • Oral Contraceptives
  • Insulin-Sensitizing Agent
Applications
  • Hospital
  • Clinic
Companies covered
  • Teva Pharmaceutical Industries Limited
  • Sanofi
  • Novartis AG
  • Merck KGaA
  • Ferring Pharmaceuticals, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • Bristol Myers Squibb Co.
  • BIOCAD
  • AstraZeneca plc.
  • Addex Therapeutics Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Dynamics
  1. 2.1 Polycystic Ovary Syndrome (PCOS) Drugs Industry Trends
  2. 2.2 Polycystic Ovary Syndrome (PCOS) Drugs Industry Drivers
  3. 2.3 Polycystic Ovary Syndrome (PCOS) Drugs Industry Opportunities and Challenges
  4. 2.4 Polycystic Ovary Syndrome (PCOS) Drugs Industry Restraints
3 Polycystic Ovary Syndrome (PCOS) Drugs Market by Manufacturers
  1. 3.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Polycystic Ovary Syndrome (PCOS) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Polycystic Ovary Syndrome (PCOS) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Polycystic Ovary Syndrome (PCOS) Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Polycystic Ovary Syndrome (PCOS) Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Polycystic Ovary Syndrome (PCOS) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Polycystic Ovary Syndrome (PCOS) Drugs Tier 1, Tier 2, and Tier 3
4 Polycystic Ovary Syndrome (PCOS) Drugs Market by Type
  1. 4.1 Polycystic Ovary Syndrome (PCOS) Drugs Type Introduction
  2. 4.1.1 Anti-Obesity
  3. 4.1.2 Antiandrogens
  4. 4.1.3 Antidepressant
  5. 4.1.4 Oral Contraceptives
  6. 4.1.5 Insulin-Sensitizing Agent
  7. 4.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type
  8. 4.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type
  12. 4.3.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Type (2021-2032)
5 Polycystic Ovary Syndrome (PCOS) Drugs Market by Application
  1. 5.1 Polycystic Ovary Syndrome (PCOS) Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application
  5. 5.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application
  9. 5.3.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Application (2021-2032)
6 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region
  1. 6.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Polycystic Ovary Syndrome (PCOS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region
  1. 7.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region
  2. 7.1.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue (2021-2032)
  8. 7.2.2 North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Limited
  2. 8.1.1 Teva Pharmaceutical Industries Limited Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Limited Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Limited Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis AG
  14. 8.3.1 Novartis AG Company Information
  15. 8.3.2 Novartis AG Business Overview
  16. 8.3.3 Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
  18. 8.3.5 Novartis AG Recent Developments
  19. 8.4 Merck KGaA
  20. 8.4.1 Merck KGaA Company Information
  21. 8.4.2 Merck KGaA Business Overview
  22. 8.4.3 Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
  24. 8.4.5 Merck KGaA Recent Developments
  25. 8.5 Ferring Pharmaceuticals, Inc.
  26. 8.5.1 Ferring Pharmaceuticals, Inc. Company Information
  27. 8.5.2 Ferring Pharmaceuticals, Inc. Business Overview
  28. 8.5.3 Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
  30. 8.5.5 Ferring Pharmaceuticals, Inc. Recent Developments
  31. 8.6 Crinetics Pharmaceuticals, Inc.
  32. 8.6.1 Crinetics Pharmaceuticals, Inc. Company Information
  33. 8.6.2 Crinetics Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
  36. 8.6.5 Crinetics Pharmaceuticals, Inc. Recent Developments
  37. 8.7 Bristol Myers Squibb Co.
  38. 8.7.1 Bristol Myers Squibb Co. Company Information
  39. 8.7.2 Bristol Myers Squibb Co. Business Overview
  40. 8.7.3 Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
  42. 8.7.5 Bristol Myers Squibb Co. Recent Developments
  43. 8.8 BIOCAD
  44. 8.8.1 BIOCAD Company Information
  45. 8.8.2 BIOCAD Business Overview
  46. 8.8.3 BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
  48. 8.8.5 BIOCAD Recent Developments
  49. 8.9 AstraZeneca plc.
  50. 8.9.1 AstraZeneca plc. Company Information
  51. 8.9.2 AstraZeneca plc. Business Overview
  52. 8.9.3 AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
  54. 8.9.5 AstraZeneca plc. Recent Developments
  55. 8.10 Addex Therapeutics Ltd.
  56. 8.10.1 Addex Therapeutics Ltd. Company Information
  57. 8.10.2 Addex Therapeutics Ltd. Business Overview
  58. 8.10.3 Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
  60. 8.10.5 Addex Therapeutics Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Polycystic Ovary Syndrome (PCOS) Drugs Value Chain Analysis
  2. 9.1.1 Polycystic Ovary Syndrome (PCOS) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Polycystic Ovary Syndrome (PCOS) Drugs Production Mode & Process
  6. 9.2 Polycystic Ovary Syndrome (PCOS) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Polycystic Ovary Syndrome (PCOS) Drugs Distributors
  9. 9.2.3 Polycystic Ovary Syndrome (PCOS) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst